Time BioVentures

BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.

NanoMosaic specializes in innovative solutions for early illness detection, prognostic monitoring, and biomarker identification. The company has developed a unique platform that utilizes nanoneedles for protein detection and quantification. This technology facilitates the analysis of multiple biomarkers on a single chip, making it possible for the medical and healthcare sectors to enhance the speed and accuracy of biomarker discovery and validation. By enabling more efficient proteomic analysis, NanoMosaic aims to improve early disease detection and monitoring, ultimately contributing to better health outcomes.

DeepSight Technology is a health technology company focused on enhancing diagnostic medical imaging through its innovative platform. Utilizing proprietary sensing technology, DeepSight combines patented hardware, software, and artificial intelligence to significantly improve image quality and extend the depth penetration of medical diagnostic ultrasounds. This advancement not only makes medical imaging safer, faster, and more affordable but also increases accessibility for healthcare providers. By offering cutting-edge sensor technology, DeepSight aims to broaden the capabilities of diagnostic ultrasounds, ultimately benefiting public health and well-being.